| Hazard Information | Back Directory | [Uses]
Tabalumab (LY2127399) is a human anti-BAFF (B-cell activating factor) monoclonal antibody (IgG4 type) with neutralising activity against membrane bound and soluble BAFF. Tabalumab can be used in studies of autoimmune diseases such as rheumatoid arthritis, renal failure and systemic lupus erythematosus[1]. | [in vivo]
Tabalumab (500 μg/rat; s.c.; single) leads to decreased B-cells and a reduction in non-canonical nF-κB signaling[1]. | Animal Model: | Human BAFF Tg mice[1]. | | Dosage: | 500 μg/rat | | Administration: | Subcutaneous injection, single. | | Result: | Significantly decreased the splenic B-cell count between day 4 and 8.
Decreased levels of p52, which returned to near the BAFF Tg level at Day 23.
|
| [References]
[1] Manetta J, et al. Generation and characterization of tabalumab, a human monoclonal antibody that neutralizes both soluble and membrane-bound B-cell activating factor. J Inflamm Res. 2014 Aug 20;7:121-31. DOI:10.2147/JIR.S67751 |
|
| Company Name: |
Biolab Reagents
|
| Telephone: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
|